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Research Problem and Background Analysis: Pain is a therapeutic challenge as well as a public health problem that is estimated to affect over 116 million American adults, reduces quality of life, and is estimated to cost up to $635 billion annually [1]. Growing recognition of the need for evidence-based, individual-centered treatment strategies raises expectations that health care will be improved by matching proven effective treatments with knowledge of patients’ unique characteristics to optimize efficacy and safety.  Essential to the goal of matching treatments to patients to enhance analgesic drug development and therapy is identification of intermediate phenotypes that capture the mechanistic complexity, genetic expression and epigenetic changes of hundreds of ongoing processes and mediators that influence treatment efficacy and safety and may form the basis for differential responses to drug therapy. The ability to identify functional variants in the genomic responses to pain and therapeutics at the sub-group and patient levels, however, has been limited to date by lack of thorough phenotyping for patients with acute pain [2]. 
The need for a more comprehensive understanding of human phenotypes has spawned a new method of phenotyping studies referred to as “deep phenotyping.” Deep phenotyping for pharmacogenomic studies requires both breath and depth to better interpret the complexities of genomic variations that may underlie individual differences in pain report.  One approach to address this complexity is to use quantitative testing of clinical features to identify more homogeneous subsets within a group of patients with a given diagnosis or characteristic. Variations in quantitative measures may identify intermediate phenotypes that are genetically less complex yet have potentially stronger signals closer to the site of gene action.  In pain, quantitative testing is often termed “quantitative sensory testing”, or QST. Another approach is to focus on patient-reported outcomes. Understanding how patients report their pain experience is essential to matching proven and effective treatments to their disease status [3]. In this experiment, patients will report their pain experience through the Patient Reported Outcomes Measurement Information System (PROMIS). This set of questionnaires comprises many domains related to pain and will help clinicians understand the effect of pain on a patient’s life. Before genomic testing and QST, PROMIS measures must be validated for pain studies. While individual questionnaires related to pain have been validated, they have not been assessed in relation to other patient experiences, thus further research is needed.  
The goal of the study was to pilot the Patient Reported Outcomes Measurement Information System (PROMIS) for pain studies. We hypothesized that self-reported responses to PROMIS domains of physical, mental, and social health in patients with pain will differ from those of healthy volunteers. Additionally, we predicted that we can categorize patients into sub-groups based off PROMIS questionnaires related to pain.
Relevant Literature: Pain is a bodily sensation that serves as a warning signal of actual or potential tissue damage. Overall, pain can be classified into three distinct neurobiological categories. First, pain classified as nociceptive is a protective system used to minimize contact with noxious stimuli. Secondly, pain can be adaptive and protective by heightening sensory sensitivity after tissue damage. This type of pain assists in healing by reducing further damage and promoting recovery and is known as inflammatory pain. Finally, pain can be maladaptive and result in abnormal functioning to the central nervous system. This type of pathological pain is characterized as a diseased sate caused by neuropathic or dysfunctional damage to the nervous system. While pain is uncomfortable, it is in many ways essential for maintaining bodily integrity. Lack of pain due to genetic mutations or excessive use of drug therapy can be harmful because pain can lose its protective role [4].  
Clinically, pain can be diagnosed as either acute or chronic. While this study focuses on acute pain in patients following the removal or third molars, there is an underlying relationship between acute and chronic pain. Acute pain is typically defined as pain that has a quick onset, can possibly be severe, and lasts a relatively short time. Chronic pain is a disease-state itself and can last over a longer period than acute pain. Chronic pain poses severe health problems to patients and many times, patients may have coexisting chronic pain conditions. By better understanding the mechanism acute pain and how acute pain transitions into chronic pain, researchers and clinicians can better target drug therapy and patient-centered treatment. 
Nociceptors are specialized sensory receptors that detect noxious stimuli and transform it into electrical signals that are conducted to the central nervous system. The process of nociception (​http:​/​​/​www.ncbi.nlm.nih.gov​/​books​/​n​/​nap13172​/​glossary​/​def-item​/​glossary.gl1-d14​/​​) involves multiple steps that are carried out by specific molecules. Some of these molecules increase pain sensitivity while others inhibit pain sensitivity. Genetic variation of these molecules alters the accuracy of the signal to and from the brain. Overall, five events are needed for a nociceptor to relay pain information to the central nervous system; signal transduction, action potential generation, transmission of the action potential to the central nervous system, second-order neuron activation to transmit the signal to the thalamus, and third-order neuron transmission of the signal to the cerebral cortex, where the nociceptive stimulus is perceived as pain. Each process is controlled by a different set of receptor proteins. By understanding the pain mechanisms existing in the human body, researchers can begin to understand how genetic variation, pain relief drugs, and other factors contribute to the pain experience [5]. 
While genomic-wide association studies (GWAS) been proven useful for identifying hundreds of loci associated with diseases and conditions, the translation of the results to clinical practice has met some difficulty [6].  As the cost of genomic and proteomic methods have declined and technological advancements continue, it is becoming routine to use genomic and proteomic scanning for discovery research. A major barrier to the identification of novel targets for investigation is the identification of phenotypes as a result of inter-individual variations. In relation to medical and clinical studies, phenotype is defined in terms of a deviation from normal morphology, physiology, or behavior [2]. The challenge in phenotyping individuals with the same clinical diagnosis is that the individuals might have entirely different sets of risk alleles, creating heterogeneous groups of potentially overlapping disorders on a genetic level.  To deal with the complexity of these heterogeneous groups, one approach is to incorporate quantitative measures to identify homogeneous subsets in a given diagnosis [7]. 
Deep phenotyping is defined as the precise and comprehensive analysis of phenotypic abnormalities in which the individual components of the phenotype are observed and described [2]. Not only does deep phenotyping involve abnormalities or variations from the norm, but also patient responses to types of treatment. Combined with existing genomic data and quantitative measures, deep phenotyping has the potential to identify clinical complexity and therapeutic implications of disease subtypes, as well as reduce the inaccuracy and misclassification of disease outcomes [2, 3]. Deep phenotyping should be engaged more for the following reasons: First, emphasis on clinical outcomes is necessary but not sufficient for the advancement of medicine. Second, analytical and biological variations tend to dilute statistical power and strength of association. Finally, phenotypes may vary across the lifespan of an individual [8]. Deep phenotyping allows for individual variations in pain reports to be better understood based on quantitative measures and genetic influences that occur during the pain experience. Individual gene mutations can now be associated with clinical diagnoses and responses to various treatments can be related to molecular pathologies. 
Conventional measures of disease status do not fully capture the ways that diseases and their treatment affect individuals [9-11]. QST and patient self-report of subjective states will be combined with the identification of pain related biomarkers to help phenotype subgroups of acute pain. The Patient-Reported Outcomes Measurement Information System (PROMIS) enables efficient and interpretable clinical trial research and clinical practice application of patient-reported outcomes. PROMIS is funded by the National Institute of Health (NIH) to improve the tools for measuring patient-reported health outcomes in clinical research by making them more valid, reliable and generalizable to patient needs [12].
















Study Design: The study was designed using the PROMIS Assessment Center. The questionnaires chosen for the study were pain interference, depression, anxiety, fatigue, physical function, sleep disturbance, pain behavior, and the ability to participate in social roles. The study was designed using IRT testing software CAT [16]. Additionally, participants were asked for demographic data related to age, ethinicity, gender, and race. 




































































Table 1: Participant Data












Plots of the data were generated comparing male and female participants. Figure 2 displays the plots from this study.






Figure 2. Particpant data to the questionnaires comapring responses based on gender. For each plot, the line represents the population norm or the score of the average American, 50. Each plot reprents the range of scores, the median, and the error for responses to each questionnaire. 
Discussion:
Reponses to the questionnaires related to the pain experience were gathered and analyzed using descriptive statistics. The participants were compared based on gender differences because females tend to report higher levels of pain than males do [17]. Overall, questionnaires related to the pain experience confirmed that a healthy population was tested. For example, in Figure 2, median score of each gender was healthier than the average American for each questionnaire except for pain behavior (female), fatigue (female), sleep disturbance (male), and anxiety (female). 
Overall, PROMIS was an efficient and useful resource for this study. The use of IRT and CAT proved to shorten the time participants spent on the questionnaire while revealing data related to how each participant compared to the average American citizen. Validity studies of PROMIS CAT and short-form questionnaires showed that CAT proved to offer greater correlation and precision when the same number of questions were answered. Based on the data, the population tested in this study was primarily healthy compared to the average American. While some mean scores were slightly unhealthy compared to the population norm, further testing will be needed to determine if this trend exists in the data. Additionally, the participant scores from this study fell within the range or scores for a validity study conducted by PROMIS except for anxiety, depression, and the ability to participate in social roles for the male population. While the scores were outside the range of the PROMIS study, participants were still healthier than the population norm score of 50 [18]. This study only had participant population of n=7 while the PROMIS validity study was conducted with thousands of participants. The low participant population might acccount for the large variance and range of responses for some participants. To determine if any trends exist or if these variations are a reflection of the population pool used in this study, more participants will be need. Further increasing the population size can uncover specific mean differences between comparable groups such as gender, age, or ethnicity. Increasing the sample size would help increase the chance of significance by better representing the population mean. While preliminary results for the use of PROMIS in pain studies have shown that the tool can be useful for identifying healthy populations related to pain, further research must be done on the pain population. 
Further steps in this study include increasing the sample size and then repeating the methods used in the study on an acute pain population. It is estimated that a population of approximately 50 particpants will be needed to determine trends and any significane from the study. Testing the pain population and comparing the demographic data to a healthy population would help reveal differences in how the pain experience affects the lives of those with acute pain. PROMIS helps to understand the physical, mental, and social impacts of pain on one’s life and researching population with acute pain can help create subgroups of the pain population based on individual experiences. To further understand the acute pain experience, genomic testing and QST will be conducted. Understanding the genetic variations in the pain experience and the individual reaction to pain, clinicians can begin the process of deep phenotying. Deep phenotyping can identify homogeneous subsets of the population that researchers and clinicians can use to improve the treatment of patients through more targeted and efficient drug therapy. This study proved important for developing a protocol for using PROMIS in pain studies. 
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Figure 1. The diamond represents the estimated score.  For each of the areas above, a score of 50 is average for the United States general population.  Most people will score between 40 and 60 and almost all people will score between 30 and 70. The Standard Error (SE) is a statistical measure of variance and represents a “margin of error” around the estimated score. The lines on either side of each diamond reflect the likely range of the actual score. 
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